MELODY

Nirsevimab for Prevention of RSV in Healthy Infants

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 1,490 healthy late-preterm and term infants, a single intramuscular dose of nirsevimab reduced medically attended RSV-associated lower-respiratory-tract infection compared with placebo.

1 490

Schéma

Double-blind RCT

Critère

Medically attended RSV-LRTI

Pertinence

Résultat1.2 % vs 5.0 %; efficacy 74.5 %.

Hammitt LL, et al. N Engl J Med. 2022;386(9):837-846. 10.1056/NEJMoa2110275

Discussion et critique

Established universal infant RSV monoclonal prophylaxis — now standard in many countries during the RSV season.